Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…